
theodoreabraham
@tabrahammd
Followers
372
Following
125
Media
13
Statuses
53
Echocardiographer and HCMologist @UCSF_Echo with stops @JHHecho @MayoClinicCV @UTSouthwestern @wakeforestmed and GOMECO. Own my tweets.
San Francisco
Joined July 2022
RT @ASE360: Let the planning begin! The #ASE2025 Program Committee is busy this weekend planning to welcome everyone to #DowntownNashville….
0
10
0
Thanks Akhil - The Power of 1 - all you need to do is convince 1 person in your ultraound circle.
@tabrahammd @ASE360 @RWASECEO @VLSorrellImages @DocStrom @ErinMichos @iamritu @KeithC_echo @purviparwani @KamuMaganti @DermotPhelanMD 20K - let’s do this!.
0
0
1
Thanks Tony - that's the spirit folks!!.
I’ll be in Nashville 2025!!! Who’s coming with me?? @ASE360 #echofirst friends??.
0
0
1
RT @ASE360: We love this #EchoMagazine article! Our ASE Leadership Academy Cohort 3 Graduates provided some encouraging words for the leade….
0
12
0
Thanks @MarbanLab; a journey greatly benefited from your tutelage and support @HopkinsMedicine.
0
0
3
RT @Cytokinetics: We’re pleased to share that the primary results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in obstructive #HCM,….
0
6
0
Delighted that you could all attend and share your wisdom.
Excited to be in NYC for @ASE360 #HCM meeting. Many new buildings since I was last in the financial district! Look forward to learn from AllisonGHaysMD @tabrahammd and others tomorrow.
0
0
8
HCM forum 2024 NYC was a Thriller! ASE knows how to have fun AND get the work done. Something to wake the group up post lunch. Thank you Carolina and Alicia @ASE360 @RWASECEO @DavidWienerMD
0
3
6
Direct view of downtown SF and Salesforce Tower from my Moffit office after demolition of Langley Porter. Not possible since 1955. @ucsf_echo @UCSFCardiology @UCSF @ASE360 @ray_stainback
0
0
2
RT @RWASECEO: What a great gathering! Thank you Dr Jae Oh and all the other KSE and AAE world leaders for expanding the use of Echo around….
0
5
0
RT @denisamuraru: Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy Don’t….
academic.oup.com
Abstract. Mavacamten is a first-in-class, targeted, cardiac-specific myosin inhibitor approved by the US Food and Drug Administration for the treatment of
0
48
0